Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation

被引:60
作者
Fan, Lan [1 ]
Wang, Jin-Chao [1 ]
Jiang, Feng [2 ]
Tan, Zhi-Rong [1 ]
Chen, Yao [1 ]
Li, Qing [1 ]
Zhang, Wei [1 ]
Wang, Guo [1 ]
Lei, He-Ping [1 ]
Hu, Dong-Li [1 ]
Wang, Dan [1 ]
Zhou, Hong-Hao [1 ]
机构
[1] Cent S Univ, Inst Clin Pharmacol, Pharmacogenet Res Inst, Changsha 410078, Hunan, Peoples R China
[2] Inje Univ, Dept Clin Pharmacol, Pusan, South Korea
基金
中国国家自然科学基金;
关键词
Baicalin; CYP2B6; Bupropion; Hydroxybupropoion; Induction; Herb-drug interaction; Pharmacokinetics; PRIMARY HUMAN HEPATOCYTES; HUMAN LIVER-MICROSOMES; IN-VITRO; CATALYTIC-ACTIVITY; P4502B6; ACTIVITY; GENETIC POLYMORPHISMS; ALLELE FREQUENCIES; DRUG INTERACTIONS; HU-TANG; CYP2B6;
D O I
10.1007/s00228-008-0594-3
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
This study investigated the effect of the herbal medicine baicalin on bupropion hydroxylation, a probe reaction for CYP2B6 activity related to different CYP2B6 genotype groups. Seventeen healthy male volunteers (6 CYP2B6*1/*1, 6 CYP2B6*1/*6, and 5 CYP2B6*6/*6) received orally administered bupropion alone and during daily treatment with baicalin. Blood samples were taken up to 72 h after each bupropion dose, and pharmacokinetics profiles were determined on days 1 and 25 for bupropion and hydroxybupropion. Baicalin administration increased hydroxybupropion maximum plasma concentration (C (max)) by 73% [90% confidence interval (CI), 44-108%; P < 0.01] and the area under the concentration time curve extrapolated to infinity (AUC(0-az)) of hydroxybupropion by 87% (90% CI, 48-137%; P < 0.01), with no change in the elimination half-life of hydroxybupropion. Baicalin increased the AUC(0-az) ratio of hydroxybupropion to bupropion by 63% (90% CI, 38-92%; P < 0.01). Baicalin significantly induced CYP2B6-catalyzed bupropion hydroxylation, and the effects of baicalin on other CYP2B6 substrate drugs deserve further investigation.
引用
收藏
页码:403 / 409
页数:7
相关论文
共 53 条
[1]
Behavioral and biochemical investigations of bupropion metabolites [J].
Bondarev, ML ;
Bondareva, TS ;
Young, R ;
Glennon, RA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 474 (01) :85-93
[2]
High-throughput liquid chromatography-tandem mass spectrometry determination of bupropion and its metabolites in human, mouse and rat plasma using a monolithic column [J].
Borges, V ;
Yang, E ;
Dunn, J ;
Henion, J .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 804 (02) :277-287
[3]
Che Qing-Ming, 2001, Zhongguo Zhongyao Zazhi, V26, P768
[4]
Haplotype structure and allele frequencies of CYP2B6 in a Korean population [J].
Cho, JY ;
Lim, HS ;
Chung, JY ;
Yu, KS ;
Kim, JR ;
Shin, SG ;
Jang, IJ .
DRUG METABOLISM AND DISPOSITION, 2004, 32 (12) :1341-1344
[5]
Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors [J].
Damaj, MI ;
Carroll, FI ;
Eaton, JB ;
Navarro, HA ;
Blough, BE ;
Mirza, S ;
Lukas, RJ ;
Martin, BR .
MOLECULAR PHARMACOLOGY, 2004, 66 (03) :675-682
[6]
A prospective safety surveillance study for bupropion sustained-release in the treatment of depression [J].
Dunner, DL ;
Zisook, S ;
Billow, AA ;
Batey, SR ;
Johnston, JA ;
Ascher, JA .
JOURNAL OF CLINICAL PSYCHIATRY, 1998, 59 (07) :366-373
[7]
The role of CYP2B6 in human xenobiotic metabolism [J].
Ekins, S ;
Wrighton, SA .
DRUG METABOLISM REVIEWS, 1999, 31 (03) :719-754
[8]
Ekins S, 1998, J PHARMACOL EXP THER, V286, P1253
[9]
The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1 [J].
Fan, L. ;
Zhang, W. ;
Guo, D. ;
Tan, Z-R ;
Xu, P. ;
Li, Q. ;
Liu, Y-Z ;
Zhang, L. ;
He, T-Y ;
Hu, D-L ;
Wang, D. ;
Zhou, H-H .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (03) :471-476
[10]
Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans [J].
Farid, Nagy A. ;
Payne, Christopher D. ;
Ernest, Steven, II ;
Li, Y. Grace ;
Winters, Kenneth J. ;
Salazar, Daniel E. ;
Small, David S. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (01) :53-59